EGFR and non-small cell lung carcinoma: compared first‐line treatments for EGFR‐mutated NSCLC, including first‐/second‐gen TKIs (e.g., gefitinib and afatinib), chemotherapy combinations, and the sole third‐gen TKI available at the time (osimertinib).